Insys Therapeutics (INSYQ) stock price, revenue, and financials

Insys Therapeutics market cap is $3.1 m, and annual revenue was $82.08 m in FY 2018

$3.1 M

INSYQ Mkt cap, 25-Mar-2020

$7.6 M

Insys Therapeutics Revenue Q1, 2019
Insys Therapeutics Gross profit (Q1, 2019)3.1 M
Insys Therapeutics Gross profit margin (Q1, 2019), %40%
Insys Therapeutics Net income (Q1, 2019)-123.8 M
Insys Therapeutics EBIT (Q1, 2019)-122.1 M
Insys Therapeutics Cash, 31-Mar-201936.5 M
Insys Therapeutics EV-21.2 M

Insys Therapeutics Revenue

Insys Therapeutics revenue was $82.08 m in FY, 2018

Embed Graph

Insys Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

99.3m222.1m330.8m242.3m140.7m82.1m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7m22.6m28.9m25.4m20.6m10.8m

Gross profit

86.6m199.5m301.9m216.9m120.1m71.3m

Gross profit Margin, %

87%90%91%90%85%87%

Sales and marketing expense

29.2m58.1m80.7m69.7m48.9m31.4m

R&D expense

8.5m33.1m55.3m73.9m63.0m57.6m

General and administrative expense

16.4m44.3m64.0m62.1m67.6m39.3m

Operating expense total

54.1m135.5m209.5m209.6m339.1m199.0m

EBIT

32.6m64.0m92.4m7.3m(219.0m)(127.7m)

EBIT margin, %

33%29%28%3%(156%)(156%)

Interest expense

928.0k153.0k538.0k1.1m1.8m1.3m

Interest income

151.0k502.0k1.0m1.9m2.0m

Pre tax profit

31.6m64.2m93.0m8.4m(217.2m)(126.4m)

Income tax expense

(8.8m)26.2m34.5m834.0k10.8m(1.9m)

Net Income

40.4m38.0m58.5m7.6m(228.0m)(124.5m)

Quarterly

USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

11.1m18.8m29.2m41.6m55.7m58.3m70.8m77.6m91.3m62.0m67.1m55.2m36.0m42.6m30.7m23.9m23.5m18.3m7.6m

Cost of goods sold

1.8m2.6m3.1m4.8m6.6m5.4m6.4m8.3m7.7m4.6m6.3m4.7m4.6m3.9m7.5m2.2m3.6m2.4m4.6m

Gross profit

9.3m16.2m26.1m36.9m49.1m52.9m64.4m69.3m83.6m57.3m60.8m50.5m31.3m38.7m23.2m21.7m19.9m16.0m3.1m

Gross profit Margin, %

84%86%89%89%88%91%91%89%92%93%91%92%87%91%76%91%85%87%40%

Sales and marketing expense

4.4m6.3m8.0m11.6m14.1m15.1m20.9m22.0m19.2m19.8m19.7m16.7m15.7m13.3m12.8m9.1m9.1m7.4m4.1m

R&D expense

1.7m1.9m1.7m4.0m9.2m7.0m10.6m17.8m12.3m20.5m22.9m16.5m12.9m14.1m19.6m12.3m16.5m14.5m10.5m

General and administrative expense

2.4m2.8m4.3m8.6m10.7m10.8m21.2m15.3m13.7m14.7m13.9m17.7m15.0m17.1m15.7m19.9m10.9m8.9m11.0m

Operating expense total

8.5m11.0m14.0m24.2m34.0m32.9m52.8m57.4m44.4m55.0m56.5m50.8m43.6m49.0m198.9m41.9m47.6m46.8m125.2m

EBIT

820.0k5.2m12.1m12.7m15.2m20.0m11.6m12.0m39.1m2.3m4.3m(328.0k)(12.3m)(10.3m)(175.7m)(20.2m)(27.7m)(30.8m)(122.1m)

EBIT margin, %

7%28%42%30%27%34%16%15%43%4%6%(1%)(34%)(24%)(573%)(85%)(118%)(168%)(1600%)

Interest expense

673.0k272.0k26.0k43.0k125.0k135.0k91.0k274.0k251.0k281.0k461.0k478.0k427.0k34.0k481.0k483.0k485.0k

Interest income

6.0k26.0k43.0k125.0k105.0k128.0k225.0k256.0k281.0k435.0k465.0k510.0k503.0k484.0k483.0k423.0k

Pre tax profit

143.0k4.9m12.1m12.7m15.2m20.1m11.8m12.1m39.2m2.6m4.6m(47.0k)(11.8m)(9.8m)(175.3m)(20.2m)(27.2m)(30.3m)(122.6m)

Income tax expense

375.0k532.0k5.0m5.7m8.6m3.7m4.8m13.1m131.0k240.0k(237.0k)(5.3m)(1.7m)(9.0m)171.0k126.0k158.0k1.2m

Net Income

143.0k4.5m11.6m7.7m9.5m11.5m8.0m7.3m26.1m2.4m4.4m190.0k(6.5m)(8.2m)(166.3m)(20.4m)(27.3m)(30.5m)(123.8m)

Insys Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

45.4m58.1m79.5m104.6m32.0m31.6m

Accounts Receivable

16.3m26.5m48.5m21.5m12.6m

Prepaid Expenses

1.7m2.2m4.0m19.8m9.4m

Inventories

14.5m34.8m41.7m21.7m17.4m8.6m

Current Assets

82.2m151.0m253.2m231.0m175.9m126.3m

PP&E

10.1m29.9m38.4m43.2m55.2m52.1m

Total Assets

100.6m215.1m351.2m356.1m279.1m192.5m

Accounts Payable

16.6m27.5m36.4m27.4m30.4m50.9m

Current Liabilities

21.1m45.7m88.9m78.6m207.2m106.9m

Total Debt

Total Liabilities

21.1m49.5m97.5m86.5m215.8m235.6m

Common Stock

5.0k354.0k719.0k719.0k736.0k744.0k

Preferred Stock

Additional Paid-in Capital

168.5m216.4m245.7m256.5m278.4m292.5m

Retained Earnings

(89.0m)(51.1m)7.4m12.7m(215.4m)(336.1m)

Total Equity

79.5m165.7m253.7m269.6m63.3m(43.1m)

Financial Leverage

1.3 x1.3 x1.4 x1.3 x4.4 x-4.5 x

Quarterly

USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

686.0k21.7m31.3m40.0m46.1m47.4m70.1m74.0m94.0m73.8m69.3m93.5m68.4m49.8m35.8m18.5m16.1m20.8m36.5m

Accounts Receivable

5.8m9.1m12.4m19.1m15.7m27.7m34.2m39.2m30.5m21.0m41.0m33.9m13.3m24.0m23.2m15.8m20.1m12.7m6.1m

Prepaid Expenses

1.0m1.0m1.5m1.7m3.0m2.7m2.7m2.5m5.8m3.9m5.4m3.7m7.0m11.6m16.5m20.2m21.1m21.4m8.5m

Inventories

8.2m8.7m11.7m19.4m24.7m31.4m35.2m35.6m39.4m32.2m29.2m28.0m21.3m20.0m18.4m16.3m10.0m10.8m7.2m

Current Assets

15.7m40.6m57.7m91.3m102.2m128.7m182.1m198.2m236.6m220.8m234.0m235.2m196.9m197.2m179.9m166.7m156.1m145.5m105.7m

PP&E

6.5m8.2m8.3m12.6m17.4m24.1m33.8m35.5m36.7m39.6m39.9m41.3m46.0m49.1m53.9m54.8m52.9m53.2m47.8m

Total Assets

22.2m48.8m66.0m122.2m149.9m188.2m247.2m275.0m314.1m325.0m338.0m353.1m337.6m337.6m323.1m253.9m235.1m217.5m172.6m

Accounts Payable

7.5m7.8m12.2m16.7m15.1m24.5m36.6m30.6m24.2m25.7m22.2m17.5m28.2m23.0m31.2m29.4m33.6m46.0m67.1m

Short-term debt

11.4m

Current Liabilities

85.7m14.6m18.5m24.9m28.3m43.2m58.8m67.3m69.6m67.5m71.3m76.6m61.9m63.1m208.9m197.8m201.6m211.4m195.2m

Long-term debt

12.2m

Total Debt

11.4m12.2m

Total Liabilities

85.7m14.6m18.5m24.9m28.3m43.2m62.6m71.1m77.5m75.0m78.8m84.3m69.8m71.2m217.1m206.6m210.5m217.4m336.3m

Common Stock

856.0k5.0k5.0k7.0k345.0k348.0k357.0k718.0k720.0k715.0k716.0k718.0k721.0k727.0k731.0k738.0k742.0k743.0k745.0k

Preferred Stock

149.0k

Additional Paid-in Capital

65.7m158.9m160.7m178.7m193.1m205.1m227.3m239.0m245.5m239.4m244.3m253.8m261.2m268.0m273.9m282.0m286.6m289.5m295.6m

Retained Earnings

(129.3m)(124.7m)(113.1m)(81.4m)(71.9m)(60.4m)(43.0m)(35.7m)(9.6m)9.9m14.2m14.4m6.1m(2.0m)(168.4m)(234.9m)(262.2m)(289.8m)(459.9m)

Total Equity

(63.5m)34.2m47.6m97.3m121.5m145.0m184.6m204.0m236.6m250.0m259.3m268.8m267.8m266.4m106.0m47.4m24.6m138.0k(163.7m)

Debt to Equity Ratio

-0.2 x-0.1 x

Debt to Assets Ratio

0.5 x0.1 x

Financial Leverage

-0.4 x1.4 x1.4 x1.3 x1.2 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x3 x5.4 x9.5 x1.6 k x-1.1 x

Insys Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

40.4m38.0m58.5m7.6m(228.0m)(124.5m)

Depreciation and Amortization

1.8m2.5m5.3m6.2m7.3m7.6m

Accounts Receivable

(13.2m)(10.2m)(21.9m)26.6m(859.0k)8.9m

Inventories

(7.4m)(20.3m)(6.9m)15.0m2.3m2.3m

Accounts Payable

14.4m50.4m52.2m(18.5m)(11.6m)15.8m

Cash From Operating Activities

24.2m49.7m100.9m58.9m(60.7m)(56.0m)

Purchases of PP&E

(5.1m)(22.2m)(13.8m)(10.6m)(16.7m)(6.1m)

Cash From Investing Activities

(5.5m)(69.9m)(88.7m)(22.0m)(17.8m)53.4m

Short-term Borrowings

11.9m

Cash From Financing Activities

26.3m32.9m9.3m(11.7m)5.8m2.1m

Net Change in Cash

45.0m12.7m21.4m25.1m(72.6m)(447.0k)

Interest Paid

51.0k

Income Taxes Paid

991.0k3.0m15.4m10.7m2.1m(13.4m)

Quarterly

USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

143.0k4.7m16.3m7.7m17.1m28.6m8.0m15.3m41.5m2.4m6.8m7.0m(6.5m)(14.7m)(181.0m)(20.4m)(47.7m)(78.2m)(123.8m)

Depreciation and Amortization

429.0k865.0k1.3m523.0k1.1m1.7m1.2m2.5m3.8m1.5m3.0m4.5m1.8m3.7m5.5m1.9m3.8m5.7m2.0m

Accounts Receivable

(2.7m)(6.0m)(9.3m)(2.7m)626.0k(11.3m)(7.6m)(12.6m)(3.9m)27.5m7.4m14.5m7.3m(3.3m)(2.6m)6.0m1.4m8.8m6.5m

Inventories

(1.1m)(1.6m)(4.7m)(4.9m)(10.2m)(16.9m)(455.0k)(772.0k)(4.6m)9.5m2.4m6.3m1.7m345.0k705.0k1.0m930.0k753.0k195.0k

Accounts Payable

2.2m1.4m5.3m9.0m19.7m41.6m17.2m29.0m26.9m(22.4m)(18.3m)(13.0m)(16.0m)(17.0m)(10.1m)(10.3m)(5.3m)11.7m16.0m

Cash From Operating Activities

930.0k3.0m13.8m6.8m21.2m33.8m16.2m32.1m74.7m12.3m9.0m34.7m(16.7m)(27.2m)(49.4m)(17.4m)(40.1m)(48.7m)(16.7m)

Purchases of PP&E

(105.0k)(2.2m)(2.8m)(3.0m)(8.4m)(15.7m)(5.2m)(8.1m)(10.7m)(2.8m)(4.6m)(7.4m)(1.9m)(9.0m)(13.6m)(760.0k)(1.9m)(4.0m)(15.0k)

Cash From Investing Activities

(105.0k)(2.2m)(2.8m)(19.9m)(37.2m)(57.4m)(11.4m)(31.2m)(56.0m)(6.1m)(7.2m)(9.8m)(20.3m)(30.7m)(23.8m)3.4m22.5m35.8m21.6m

Short-term Borrowings

500.0k11.9m

Cash From Financing Activities

(500.0k)20.6m19.9m7.7m16.8m25.7m7.2m15.0m17.1m(11.9m)(12.0m)(10.9m)654.0k3.2m4.3m524.0k1.7m1.8m18.0k

Net Change in Cash

325.0k21.4m31.0m(5.4m)757.0k2.0m12.0m15.9m35.9m(5.7m)(10.2m)14.0m(36.3m)(54.8m)(68.9m)(13.4m)(15.9m)(11.2m)5.0m

Interest Paid

Income Taxes Paid

2.2m2.2m3.4m6.4m2.5m6.6m9.3m14.0k1.8m1.9m43.0k(7.0k)(7.0k)(66.0k)

Insys Therapeutics Ratios

USDQ1, 2013

Debt/Equity

-0.2 x

Debt/Assets

0.5 x

Financial Leverage

-0.4 x

Insys Therapeutics Employee Rating

2.171 votes
Culture & Values
1.8
Work/Life Balance
2.7
Senior Management
1.9
Salary & Benefits
2.5
Career Opportunities
1.9
Source